Long-Term Safety Follow-Up Of Subjects Previously Enrolled In Rheumatoid Arthritis Studies Of CP-690,550
NCT ID: NCT00414661
Last Updated: 2013-01-01
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
162 participants
OBSERVATIONAL
2007-04-30
2012-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study To Evaluate The Mechanism Of Action Of CP-690,550 In Patients With Rheumatoid Arthritis
NCT00976599
Evaluation of Tumour Necrosis Factor Alpha (TNFα) Blockers in Early Rheumatoid Arthritis in France
NCT02927509
Evaluation of TNFα Blockers Monotherapy in Early Rheumatoid Arthritis in France
NCT02927535
This is a Retrospective Observational Study Looking at the Characteristics and Outcomes of Participants Taking Inflectra Using the CorEvitas Rheumatoid Arthritis Registry
NCT05375942
Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX
NCT01039688
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Study group
All enrolled subjects
CP-690,550
Subjects had to have received CP-690,550 or other blinded study drug in index study. No intervention in this long-term follow-up trial.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CP-690,550
Subjects had to have received CP-690,550 or other blinded study drug in index study. No intervention in this long-term follow-up trial.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Gilbert, Arizona, United States
Pfizer Investigational Site
Tucson, Arizona, United States
Pfizer Investigational Site
Palo Alto, California, United States
Pfizer Investigational Site
San Diego, California, United States
Pfizer Investigational Site
Stanford, California, United States
Pfizer Investigational Site
Upland, California, United States
Pfizer Investigational Site
Ocala, Florida, United States
Pfizer Investigational Site
Orlando, Florida, United States
Pfizer Investigational Site
Sarasota, Florida, United States
Pfizer Investigational Site
Tampa, Florida, United States
Pfizer Investigational Site
Tampa, Florida, United States
Pfizer Investigational Site
Venice, Florida, United States
Pfizer Investigational Site
Rockford, Illinois, United States
Pfizer Investigational Site
Lincoln, Nebraska, United States
Pfizer Investigational Site
Albany, New York, United States
Pfizer Investigational Site
Hickory, North Carolina, United States
Pfizer Investigational Site
Hickory, North Carolina, United States
Pfizer Investigational Site
Wyomissing, Pennsylvania, United States
Pfizer Investigational Site
Mesquite, Texas, United States
Pfizer Investigational Site
Tacoma, Washington, United States
Pfizer Investigational Site
Tacoma, Washington, United States
Pfizer Investigational Site
Buenos Aires, , Argentina
Pfizer Investigational Site
Buenos Aires, , Argentina
Pfizer Investigational Site
Goiânia, Goiás, Brazil
Pfizer Investigational Site
Rio de Janeiro, Rio de Janeiro, Brazil
Pfizer Investigational Site
São Paulo, São Paulo, Brazil
Pfizer Investigational Site
São Paulo, São Paulo, Brazil
Pfizer Investigational Site
Sofia, , Bulgaria
Pfizer Investigational Site
Victoria, British Columbia, Canada
Pfizer Investigational Site
Santiago, RM, Chile
Pfizer Investigational Site
Santiago, RM, Chile
Pfizer Investigational Site
Providencia, Santiago, RM, Chile
Pfizer Investigational Site
Brno, , Czechia
Pfizer Investigational Site
České Budějovice, , Czechia
Pfizer Investigational Site
Prague, , Czechia
Pfizer Investigational Site
Prague, , Czechia
Pfizer Investigational Site
Praha 11 - Chodov, , Czechia
Pfizer Investigational Site
Santo Domingo, Santo Domingo Province, Dominican Republic
Pfizer Investigational Site
Hyvinkää, , Finland
Pfizer Investigational Site
Athens, Goudi, Greece
Pfizer Investigational Site
Thessaloniki, , Greece
Pfizer Investigational Site
Budapest, , Hungary
Pfizer Investigational Site
Szolnok, , Hungary
Pfizer Investigational Site
Veszprém, , Hungary
Pfizer Investigational Site
Ahmedabad, Gujarat, India
Pfizer Investigational Site
Mangalore, Karnataka, India
Pfizer Investigational Site
Pune, Maharashtra, India
Pfizer Investigational Site
Florence, , Italy
Pfizer Investigational Site
Genova, , Italy
Pfizer Investigational Site
Kitakyushu, Fukuoka, Japan
Pfizer Investigational Site
Higashihiroshima, Hiroshima, Japan
Pfizer Investigational Site
Sagamihara, Kanagawa, Japan
Pfizer Investigational Site
Shinjyuku-ku, Tokyo, Japan
Pfizer Investigational Site
México, D.f., Mexico
Pfizer Investigational Site
Mexico City, Mexico City, Mexico
Pfizer Investigational Site
Bialystok, , Poland
Pfizer Investigational Site
Poznan, , Poland
Pfizer Investigational Site
Sopot, , Poland
Pfizer Investigational Site
Warsaw, , Poland
Pfizer Investigational Site
Wroclaw, , Poland
Pfizer Investigational Site
San Juan, , Puerto Rico
Pfizer Investigational Site
Bratislava, , Slovakia
Pfizer Investigational Site
Piešťany, , Slovakia
Pfizer Investigational Site
Žilina, , Slovakia
Pfizer Investigational Site
Daejeon, , South Korea
Pfizer Investigational Site
Gwangju, , South Korea
Pfizer Investigational Site
Incheon, , South Korea
Pfizer Investigational Site
Seoul, , South Korea
Pfizer Investigational Site
Seoul, , South Korea
Pfizer Investigational Site
Seoul, , South Korea
Pfizer Investigational Site
Guadalajara, Guadalajara, Spain
Pfizer Investigational Site
Vinnitsa, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A3921029
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.